Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study
Main Author: | James R. Crandell |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-07-01
|
Series: | Clinical Medicine Insights: Cardiology |
Online Access: | http://www.la-press.com/switching-from-epa--dha-omega-3-acid-ethyl-esters-to-high-purity-epa-i-article-a5790 |
Similar Items
-
Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study
by: James R. Crandell
Published: (2016-01-01) -
Attenuation of Metabolic Syndrome by EPA/DHA Ethyl Esters in Testosterone-Deficient Obese Rats
by: Nikhil S. Bhandarkar, et al.
Published: (2018-05-01) -
Effect Of Epa Ethyl Ester On Fatty Acid Profile In Hemodialysis Patients With Low Epa/Aa Ratio
by: Fumitaka Ebihara, et al.
Published: (2012-06-01) -
Production of EPA and DHA with fungi
by: 陳滿燕
Published: (1998) -
Synthesis of DHA/EPA Ethyl Esters via Lipase-Catalyzed Acidolysis Using Novozym<sup>®</sup> 435: A Kinetic Study
by: Chia-Hung Kuo, et al.
Published: (2020-05-01)